American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Perales
    Perales
  5. Tallman
    Tallman
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Palomba
    Palomba
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (3997)
  2. Hematologic Malignancies, Division of (3800)
  3. Center for Hematologic Malignancies (3677)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1341)
  6. Sloan Kettering Institute Faculty (1075)
  7. Bone Marrow Transplant (986)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (955)
  9. Lymphoma (940)
  10. Tow Center for Developmental Oncology (TCDO) (882)
Search Within
Formats
  1. Meeting Abstract (4150)
  2. Journal Article (1255)
  3. Research Letter (46)
  4. Review (44)
  5. Editorial (35)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (3997)
  2. Hematologic Malignancies, Division of (3800)
  3. Center for Hematologic Malignancies (3677)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1341)
  6. Sloan Kettering Institute Faculty (1075)

More Groups

People
  1. Sergio Giralt (348)
  2. Andrew Zelenetz (341)
  3. Ross Levine (316)
  4. Miguel-Angel Perales (311)
  5. Martin Tallman (301)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (62)
  2. 2024 (428)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (5172)
  2. Blood Advances (331)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5553)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase III randomized trial for frail newly diagnosed multiple myeloma patients comparing bortezomib-lenalidomide-dexamethasone (VRd-lite followed by len maintenance) with daratumumab-lenalidomide-dexamethasone (DRd followed by len+/- dara maintenance): SWOG S2209
    Meeting Abstract

    Ailawadhi, S.; Hoering, A.; Ye, J. C.; Lipe, B.; Chauncey, T. R.; Gowin, K.; Calverley, D.; Holstein, S. A.; Campagnaro, E. L.; Rosenthal, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Results from the Great Britain AML real world evidence (ARC) initiative - A centre-based chart review study to assess treatment outcomes of venetoclax for the treatment of acute myeloid leukemia
    Meeting Abstract

    O'Nions, J.; Errico, G.; Floro, L.; Murthy, V.; Sweeney, C.; Kaur, H.; Mohite, U.; Ayto, R.; Alvares, C.; Goldberg, A. D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A phase III, randomized study of daratumumab, cyclophosphamide, bortezomib and dexamethasone (DARA-VCD) induction followed by autologous stem cell transplant or Dara-VCD consolidation and daratumumab maintenance in patients with newly diagnosed AL amyloidosis
    Meeting Abstract

    Hagen, P.; Sidana, S.; Parker, T. L.; Walker, B. A.; Sanchorawala, V.; Zonder, J. A.; Kourelis, T.; D'Souza, A.; Landau, H. J.; Rosenthal, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Real-world safety and efficacy of talquetamab for patients with heavily pretreated relapsed-refractory multiple myeloma
    Meeting Abstract

    Shaikh, H.; Lochner, J.; Loeffler, B.; Friend, R.; Habib, A.; McKenna, M.; Snyder, J.; Davis, J. A.; Patrus, G.; Dileo, R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Validation of recent response criteria (ELN-22, IWG-23 and PB-CR) in 1634 MDS/CMML/AML patients treated with HMA or HMA-VEN using CPH models and a CPH deep neural network - Can or should response criteria be harmonized for similarly treated patients?
    Meeting Abstract

    Pleyer, L.; Vaisband, M.; Klammer, P.; Drost, M.; Angermann, H.; Keil, F.; Petzer, V.; Heibl, S.; Moritz, J.; Girschikofsky, M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Efficacy of BCMA T-cell engagers (TCE) vs. chimeric antigen receptor T-cell therapy (CAR-T) following BCMA-directed therapies, relapsed/refractory multiple myeloma: The chicken or the egg dilemma
    Meeting Abstract

    Snyder, J.; Ahmed, N.; Mahmoudjafari, Z.; Abdallah, A.; McGuirk, J. P.; Mushtaq, M. U.; Habib, A.; Khan, A. M.; Laharwal, M. M.; Mewawalla, P.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Optimizing therapeutic outcome of CD19(T2)28z1XX chimeric antigen receptor (CAR) T in adult patients with large B-cell lymphoma through a quantitative medicine approach
    Meeting Abstract

    Dey, A.; Li, J.; Park, J. H.; Sellner, L.; Sundaresan, V.; Palomba, M. L.; Mansilla-Soto, J.; Senechal, B.; Wang, X.; Sikder, D. S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Bridging radiotherapy may decrease inflammation prior to CAR-T cell therapy
    Meeting Abstract

    Patel, R. R.; Tward, A.; Fregonese, B.; Hubbeling, H.; Lapen, K.; Mankuzhy, N. P.; Raj, S. S.; Perales, M. A.; Shouval, R.; Yahalom, J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Confirmatory efficacy and safety evaluation of MB-105, a CD5.CAR T therapy: Multicenter phase 2 study in patients with relapsed/refractory T cell lymphoma (R/R TCL)
    Meeting Abstract

    Iyer, S. P.; Hill, L.; Horwitz, S.; Jain, S.; Poh, C.; Vose, J. M.; Brenner, M. K.; Mamonkin, M.; Hein, S.; Giordano, F.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A phase 2B, open-label multicenter study of tebapivat (AG-946), a potent pyruvate kinase activator, in patients
    Meeting Abstract

    Zeidan, A. M.; Sekeres, M. A.; Al-Samkari, H.; Carraway, H. E.; DeZern, A. E.; Mittelman, M.; Little, M.; Beynon, V.; Dai, X.; Sommakia, S.; more...
    Blood (2024)

    Fulltext@MSK | Save